Journal Article
. 2021 Jun; 22(7):946-958.
doi: 10.1016/S1470-2045(21)00241-2.

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

Chung-Han Lee 1 Amishi Yogesh Shah 2 Drew Rasco 3 Arpit Rao 4 Matthew H Taylor 5 Christopher Di Simone 6 James J Hsieh 7 Alvaro Pinto 8 David R Shaffer 9 Regina Girones Sarrio 10 Allen Lee Cohn 11 Nicholas J Vogelzang 12 Mehmet Asim Bilen 13 Sara Gunnestad Ribe 14 Musaberk Goksel 15 Øyvind Krohn Tennøe 16 Donald Richards 17 Randy F Sweis 18 Jay Courtright 19 Daniel Heinrich 20 Sharad Jain 21 Jane Wu 22 Emmett V Schmidt 23 Rodolfo F Perini 23 Peter Kubiak 24 Chinyere E Okpara 25 Alan D Smith 25 Robert J Motzer 26 
Affiliations
  • PMID: 34143969
  •     20 References
  •     11 citations

Abstract

Background: Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune checkpoint inhibitors (ICIs). Pembrolizumab and lenvatinib are active as monotherapies in RCC; thus, we aimed to evaluate the combination of lenvatinib plus pembrolizumab in these patients.

Methods: We report results of the metastatic RCC cohort from an open-label phase 1b/2 study of lenvatinib plus pembrolizumab in patients aged at least 18 years with selected solid tumours and an Eastern Cooperative Oncology Group performance status of 0-1. Oral lenvatinib at 20 mg was given once daily along with intravenous pembrolizumab at 200 mg once every 3 weeks. Patients remained on study drug treatment until disease progression, development of unacceptable toxicity, or withdrawal of consent. Efficacy was analysed in patients with clear cell metastatic RCC receiving study drug by previous therapy grouping: treatment naive, previously treated ICI naive (previously treated with at least one line of therapy but not with an anti-PD-1 or anti-PD-L1 ICI), and ICI pretreated (ie, anti-PD-1 or anti-PD-L1) patients. Safety was analysed in all enrolled and treated patients. The primary endpoint was the objective response rate at week 24 per immune-related Response Evaluation Criteria In Solid Tumors (irRECIST) by investigator assessment. This trial is registered with ClinicalTrials.gov (NCT02501096) and with the EU Clinical Trials Register (EudraCT2017-000300-26), and is closed to new participants.

Findings: Between July 21, 2015, and Oct 16, 2019, 145 patients were enrolled in the study. Two patients had non-clear cell RCC and were excluded from the efficacy analysis (one in the treatment-naive group and one in the ICI-pretreated group); thus, the population evaluated for efficacy comprised 143 patients (n=22 in the treatment-naive group, n=17 in the previously treated ICI-naive group, and n=104 in the ICI-pretreated group). All 145 enrolled patients were included in the safety analysis. The median follow-up was 19·8 months (IQR 14·3-28·4). The number of patients with an objective response at week 24 by irRECIST was 16 (72·7%, 95% CI 49·8-89·3) of 22 treatment-naive patients, seven (41·2%, 18·4-67·1) of 17 previously treated ICI-naive patients, and 58 (55·8%, 45·7-65·5) of 104 ICI-pretreated patients. Of 145 patients, 82 (57%) had grade 3 treatment-related adverse events and ten (7%) had grade 4 treatment-related adverse events. The most common grade 3 treatment-related adverse event was hypertension (30 [21%] of 145 patients). Treatment-related serious adverse events occurred in 36 (25%) patients, and there were three treatment-related deaths (upper gastrointestinal haemorrhage, sudden death, and pneumonia).

Interpretation: Lenvatinib plus pembrolizumab showed encouraging antitumour activity and a manageable safety profile and might be an option for post-ICI treatment of metastatic RCC.

Funding: Eisai and Merck Sharp & Dohme.

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
Yu Kato, Kimiyo Tabata, +13 authors, Yasuhiro Funahashi.
PLoS One, 2019 Feb 28; 14(2). PMID: 30811474    Free PMC article.
Highly Cited.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Robert Motzer, Boris Alekseev, +36 authors, CLEAR Trial Investigators.
N Engl J Med, 2021 Feb 23; 384(14). PMID: 33616314
Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes.
Robert Roskoski.
Pharmacol Res, 2015 Nov 04; 103. PMID: 26529477
Highly Cited. Review.
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
Anita Gul, Tyler F Stewart, +10 authors, Brian I Rini.
J Clin Oncol, 2020 Jun 04; 38(27). PMID: 32491962    Free PMC article.
Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma.
Chengkuan Cai, Jingyuan Tang, +6 authors, Zhongqing Wei.
Exp Ther Med, 2017 Sep 16; 14(4). PMID: 28912872    Free PMC article.
Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
Masahiro Matsuki, Taisuke Hoshi, +4 authors, Junji Matsui.
Cancer Med, 2018 May 08; 7(6). PMID: 29733511    Free PMC article.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Brian I Rini, Elizabeth R Plimack, +25 authors, KEYNOTE-426 Investigators.
N Engl J Med, 2019 Feb 20; 380(12). PMID: 30779529
Highly Cited.
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
Vicky Makker, Matthew H Taylor, +16 authors, Antonio Casado Herraez.
J Clin Oncol, 2020 Mar 14; 38(26). PMID: 32167863    Free PMC article.
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Takayuki Kimura, Yu Kato, +10 authors, Kenichi Nomoto.
Cancer Sci, 2018 Nov 18; 109(12). PMID: 30447042    Free PMC article.
Systemic Therapy for Metastatic Renal-Cell Carcinoma.
Toni K Choueiri, Robert J Motzer.
N Engl J Med, 2017 Jan 26; 376(4). PMID: 28121507
Highly Cited. Review.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Toni K Choueiri, Thomas Powles, +29 authors, CheckMate 9ER Investigators.
N Engl J Med, 2021 Mar 04; 384(9). PMID: 33657295    Free PMC article.
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
Robert J Motzer, Thomas E Hutson, +14 authors, James Larkin.
Lancet Oncol, 2015 Oct 21; 16(15). PMID: 26482279
Highly Cited.
Renal cell carcinoma.
James J Hsieh, Mark P Purdue, +6 authors, Vincenzo Ficarra.
Nat Rev Dis Primers, 2017 Mar 10; 3. PMID: 28276433    Free PMC article.
Highly Cited. Review.
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma.
Elie Rassy, Ronan Flippot, Laurence Albiges.
Ther Adv Med Oncol, 2020 Mar 28; 12. PMID: 32215057    Free PMC article.
Review.
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.
David F McDermott, Jae-Lyun Lee, +16 authors, Michael B Atkins.
J Clin Oncol, 2021 Feb 03; 39(9). PMID: 33529058    Free PMC article.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Nizar M Tannir, +30 authors, CheckMate 214 Investigators.
N Engl J Med, 2018 Mar 22; 378(14). PMID: 29562145    Free PMC article.
Highly Cited.
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Robert J Motzer, Konstantin Penkov, +25 authors, Toni K Choueiri.
N Engl J Med, 2019 Feb 20; 380(12). PMID: 30779531    Free PMC article.
Highly Cited.
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Lesley Seymour, Jan Bogaerts, +16 authors, RECIST working group.
Lancet Oncol, 2017 Mar 09; 18(3). PMID: 28271869    Free PMC article.
Highly Cited. Review.
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma.
Praful Ravi, Charlene Mantia, +14 authors, Toni K Choueiri.
JAMA Oncol, 2020 May 30; 6(10). PMID: 32469396    Free PMC article.
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
Matthew H Taylor, Chung-Han Lee, +6 authors, Robert J Motzer.
J Clin Oncol, 2020 Jan 22; 38(11). PMID: 31961766    Free PMC article.
Rapid Response to the Combination of Lenvatinib and Sintilimab in a Pancreatic Acinar Cell Carcinoma Patient With Elevated Alpha-Fetoprotein: A Case Report.
Lanqun Qin, Jie Shen, Yueling Yang, Zhengyun Zou.
Front Oncol, 2021 Nov 09; 11. PMID: 34745936    Free PMC article.
Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers.
Brian W Labadie, Arjun V Balar, Jason J Luke.
Cancers (Basel), 2021 Nov 14; 13(21). PMID: 34771578    Free PMC article.
Review.
From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma.
Jonathan Anker, Justin Miller, +2 authors, Che-Kai Tsao.
Cells, 2021 Nov 28; 10(11). PMID: 34831452    Free PMC article.
Review.
Signal pathways of melanoma and targeted therapy.
Weinan Guo, Huina Wang, Chunying Li.
Signal Transduct Target Ther, 2021 Dec 21; 6(1). PMID: 34924562    Free PMC article.
Review.
Single-cell transcriptomics reveals a low CD8+ T cell infiltrating state mediated by fibroblasts in recurrent renal cell carcinoma.
Yu-Lu Peng, Long-Bin Xiong, +19 authors, Zhi-Ling Zhang.
J Immunother Cancer, 2022 Feb 06; 10(2). PMID: 35121646    Free PMC article.
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?
Jacob J Adashek, Joshua J Breunig, +6 authors, Jun Gong.
Drugs, 2022 Feb 18; 82(4). PMID: 35175588
Review.
Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.
Qi Li, Mengran Cao, +9 authors, Jinzhang Chen.
Front Oncol, 2022 Mar 15; 12. PMID: 35280760    Free PMC article.
Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure.
Ning Zan, Xuan Zhang, +4 authors, Fusheng Gou.
Front Oncol, 2022 Mar 18; 12. PMID: 35296012    Free PMC article.
Cancer combination therapies by angiogenesis inhibitors; a comprehensive review.
Mohammad Javed Ansari, Dmitry Bokov, +9 authors, Mehdi Dadashpour.
Cell Commun Signal, 2022 Apr 09; 20(1). PMID: 35392964    Free PMC article.
Review.
Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis.
Yuanquan Yang, Sherry V Mori, +5 authors, Ming Yin.
Cancer Med, 2022 Feb 10; 11(7). PMID: 35138046    Free PMC article.
Systematic Review.
Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.
Kevin Lu, Kun-Yuan Chiu, Chen-Li Cheng.
Cancer Treat Res, 2022 May 14; 183. PMID: 35551661